Actavis Acquires Worldwide Rights for Palau Pharma's Albaconazole Antifungal Agent

Actavis, Inc. (NYSE: ACT ) and Palau Pharma, S.A. today announced that Actavis Specialty Brands has acquired worldwide rights to Palau Pharma's Albaconazole development product, an oral antifungal agent for the treatment of vulvo-vaginal candidiasis, onychomycosis and other antifungal applications. Albaconazole is a new oral triazole discovered at